PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

PLGA based cancer immunotherapy incorporating antigen and TLR ligands has resulted in enhancement of the anti-tumour response. Here, the authors explore the use of a defined double stranded RNA adjuvant, Riboxxim, and test its incorporation with PLGA immunotherapy in the context of in vivo tumour mo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia Koerner, Dennis Horvath, Valerie L. Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, Marcus Groettrup
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/49f713706d4f4e6c84d91492aa8a5fb5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49f713706d4f4e6c84d91492aa8a5fb5
record_format	dspace
spelling	oai:doaj.org-article:49f713706d4f4e6c84d91492aa8a5fb52021-12-02T15:45:24ZPLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy10.1038/s41467-021-23244-32041-1723https://doaj.org/article/49f713706d4f4e6c84d91492aa8a5fb52021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23244-3https://doaj.org/toc/2041-1723PLGA based cancer immunotherapy incorporating antigen and TLR ligands has resulted in enhancement of the anti-tumour response. Here, the authors explore the use of a defined double stranded RNA adjuvant, Riboxxim, and test its incorporation with PLGA immunotherapy in the context of in vivo tumour models and show enhanced induction of the anti-tumour response.Julia KoernerDennis HorvathValerie L. HerrmannAnna MacKerracherBruno GanderHideo YagitaJacques RohayemMarcus GroettrupNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Julia Koerner Dennis Horvath Valerie L. Herrmann Anna MacKerracher Bruno Gander Hideo Yagita Jacques Rohayem Marcus Groettrup PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
description	PLGA based cancer immunotherapy incorporating antigen and TLR ligands has resulted in enhancement of the anti-tumour response. Here, the authors explore the use of a defined double stranded RNA adjuvant, Riboxxim, and test its incorporation with PLGA immunotherapy in the context of in vivo tumour models and show enhanced induction of the anti-tumour response.
format	article
author	Julia Koerner Dennis Horvath Valerie L. Herrmann Anna MacKerracher Bruno Gander Hideo Yagita Jacques Rohayem Marcus Groettrup
author_facet	Julia Koerner Dennis Horvath Valerie L. Herrmann Anna MacKerracher Bruno Gander Hideo Yagita Jacques Rohayem Marcus Groettrup
author_sort	Julia Koerner
title	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
title_short	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
title_full	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
title_fullStr	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
title_full_unstemmed	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
title_sort	plga-particle vaccine carrying tlr3/rig-i ligand riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/49f713706d4f4e6c84d91492aa8a5fb5
work_keys_str_mv	AT juliakoerner plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT dennishorvath plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT valerielherrmann plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT annamackerracher plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT brunogander plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT hideoyagita plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT jacquesrohayem plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy AT marcusgroettrup plgaparticlevaccinecarryingtlr3rigiligandriboxximsynergizeswithimmunecheckpointblockadeforeffectiveanticancerimmunotherapy
_version_	1718385746078859264

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

Ejemplares similares